Literature DB >> 18692642

Gene expression profiling from endomyocardial biopsy tissue allows distinction between subentities of dilated cardiomyopathy.

Volker Ruppert1, Thomas Meyer, Sabine Pankuweit, Eva Möller, Reinhard C Funck, Wolfram Grimm, Bernhard Maisch.   

Abstract

OBJECTIVE: Expression profile analysis using endomyocardial biopsy specimens from patients with cardiomyopathies promises to improve the differential diagnosis of heart failure.
METHODS: In this study, left ventricular endomyocardial biopsy specimens were obtained from 50 patients and histopathologically classified according to the World Heart Federation Task Force criteria as having dilated cardiomyopathy (n = 17), inflammatory cardiomyopathy (n = 11), myocarditis (n = 15), or pericarditis (n = 7). Microarrays were performed by hybridization of synthesized complementary DNA against a Lab-Arraytor60-combi microarray (SIRS-Lab, Jena, Switzerland). Differentially expressed genes were clustered hierarchically according to their variation in hybridization signals.
RESULTS: In samples from patients with dilated cardiomyopathy, two different types of gene expression profiles were distinguishable. One pattern was unique for dilated cardiomyopathy and inflammatory cardiomyopathy, respectively, and the other more closely resembled that seen in samples from inflammatory heart disease. Additionally, we confirmed the microarray data by showing that dilated cardiomyopathy is associated with a reduced myocardial toll-like receptor 9 expression that resulted from progressive loss of functional cardiomyocytes. Taken together, our data demonstrate the utility and validity of microarrays from endomyocardial biopsy specimens in detecting subentities of dilated cardiomyopathy that do not differ histopathologically, but transcriptionally, from each other. The gene expression profile observed in one subgroup of patients with dilated cardiomyopathy is indicative of ongoing immune activation, albeit infiltrating immunocompetent cells were not detected histopathologically.
CONCLUSION: Thus, our transcriptional data indicate that dilated cardiomyopathy constitutes a heterogeneous disease with an broad overlap to inflammatory heart disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18692642     DOI: 10.1016/j.jtcvs.2008.03.016

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  4 in total

1.  Gene expression profiling in peripheral blood nuclear cells in patients with refractory ischaemic end-stage heart failure.

Authors:  S Szmit; M Jank; H Maciejewski; M Grabowski; R Glowczynska; A Majewska; K J Filipiak; T Motyl; G Opolski
Journal:  J Appl Genet       Date:  2010       Impact factor: 3.240

2.  Transcriptomic biomarkers for the accurate diagnosis of myocarditis.

Authors:  Bettina Heidecker; Michelle M Kittleson; Edward K Kasper; Ilan S Wittstein; Hunter C Champion; Stuart D Russell; Ralph H Hruban; E Rene Rodriguez; Kenneth L Baughman; Joshua M Hare
Journal:  Circulation       Date:  2011-03-07       Impact factor: 29.690

Review 3.  Molecular signatures and the study of gene expression profiles in inflammatory heart diseases.

Authors:  V Ruppert; B Maisch
Journal:  Herz       Date:  2012-09       Impact factor: 1.443

Review 4.  Epigenomic and transcriptomic approaches in the post-genomic era: path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart.

Authors:  Cinzia Perrino; Albert-Laszló Barabási; Gianluigi Condorelli; Sean Michael Davidson; Leon De Windt; Stefanie Dimmeler; Felix Benedikt Engel; Derek John Hausenloy; Joseph Addison Hill; Linda Wilhelmina Van Laake; Sandrine Lecour; Jonathan Leor; Rosalinda Madonna; Manuel Mayr; Fabrice Prunier; Joost Petrus Geradus Sluijter; Rainer Schulz; Thomas Thum; Kirsti Ytrehus; Péter Ferdinandy
Journal:  Cardiovasc Res       Date:  2017-06-01       Impact factor: 10.787

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.